Imagine a world where children are protected from painful illnesses caused by the chikungunya virus. This virus can lead to debilitating symptoms like fever and joint pain, making it tough for kids to enjoy their daily activities. In a new study, a vaccine designed to fight this virus is being tested in children aged 1 to under 12 years. The goal is to see if the vaccine is safe and effective at helping their bodies build defenses against chikungunya. Researchers will track any side effects and measure how well the vaccine works after administration. If successful, this vaccine could mean fewer hospital visits and healthier kids, giving families peace of mind. However, it's important to remember that this is still in the testing phase. While the potential is exciting, we need to wait for the results before we can celebrate a new tool in protecting our children from chikungunya.
Could a New Vaccine Protect Children from Chikungunya Virus?
Plain Language Summary
What this means for you:
A new vaccine could be a game-changer in protecting children from chikungunya virus and its painful effects. What this means for you:
A new vaccine could be a game-changer in protecting children from chikungunya virus and its painful effects. View Original Abstract ↓
Status: RECRUITING | Phase: PHASE3
Condition(s): Chikungunya Virus
Intervention(s): CHIKV VLP vaccine (BIOLOGICAL), Placebo (BIOLOGICAL)
The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 1 to \<12 years of age.
Primary Outcome(s): Safety Endpoint 3: Incidence of AESI, MAAEs, and SAEs; Primary Immunogenicity Endpoint: Day 22 anti-CHIKV SNA seroresponse rate in seronegative children; Safety Endpoint 2: Incidence of unsolicited AEs through Day 29
Enrollment: 720 (ESTIMATED)
Lead Sponsor: Bavarian Nordic
Start: 2025-06-05 | Primary Completion: 2028-12